Der p2 B细胞表位RNA疫苗制备及其对过敏性鼻炎小鼠特异性IgE抑制作用

doi:10.6040/j.issn.1673-3770.0.2024.170

摘要/Abstract

摘要： 目的尘螨过敏原Der p2 B细胞表位RNA疫苗的制备及其对过敏性鼻炎小鼠特异性IgE影响。方法经表位预测软件分析预测Der p2蛋白序列上B细胞表位肽,合成B细胞表位肽并进行体外IgE反应性分析,将B细胞表位肽与载体蛋白相连,构建B细胞表位RNA疫苗,RNA疫苗经脂质体包裹后,皮下注射给予过敏性鼻炎小鼠进行治疗,检测小鼠外周血特异性IgE、IgG4水平及Treg、Th17细胞变化。结果与Der p2阳性对照组相比,预测的四段B细胞表位肽均显示出低IgE反应性,差异具有统计学意义(P<0.001);与过敏性鼻炎组小鼠相比,经Der p2 B细胞表位RNA疫苗治疗后,血清特异性IgE水平明显下降,IgG4水平升高,差异具有统计学意义(P<0.05);同时,治疗后外周血中Treg比率有所增加,Th17比率降低,差异具有统计学意义(P<0.05)。结论成功构建了Der p2 B细胞表位RNA疫苗,并可有效降低过敏性鼻炎小鼠外周血特异性IgE,提高中和型抗体IgG4水平及Treg比率。

关键词: 尘螨, B细胞表位, RNA疫苗, 特异性IgE

Abstract: Objective This study aimed to construct a house dust mite allergen Der p 2 B cell epitope RNA vaccine and evaluate its inhibitory potency against antigen-specific IgE in allergic rhinitis mice. Methods Epitope prediction software was utilized to predict potential B-cell epitope peptides on the Der p2 protein sequence, followed by synthesis of these peptides and analysis of their IgE reactivity in vitro. The B-cell epitope peptide was then linked with a carrier protein to construct the B-cell epitope RNA vaccine, which was administered to allergic rhinitis mice via subcutaneous injection. Levels of specific IgE, IgG4, Treg, and Th17 cells in the peripheral blood of the mice were subsequently tested. Results Compared with the recombinant Der p2 positive control group, the predicted four B cell epitope peptides exhibited significantly lower IgE reactivity(P<0.001). Furthermore, treatment with the Der p2 B cell epitope RNA vaccine led to a significant decrease in serum levels of specific IgE and an increase in IgG4 compared to mice in the allergic rhinitis group(P<0.05). Additionally, there was an increase in Treg ratio and a reduction in Th17 ratio after treatment(P<0.05). Conclusion The construction of the Der p2 B cell epitope RNA vaccine has been successfully achieved and it effectively reduces specific IgE levels while increasing neutralizing antibody levels and Treg ratios in peripheral blood of allergic rhinitis mice.

Key words: house dust mite, B cell epitope, RNA vaccine, specific IgE

中图分类号:

R765.21

杨贵,胡田勇,贺海鹏,马莉,魏海峰,黄佳敏,刘志强. Der p2 B细胞表位RNA疫苗制备及其对过敏性鼻炎小鼠特异性IgE抑制作用[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 6-12.

YANG Gui, HU Tianyong, HE Haipeng, MA Li, WEI Haifeng, HUANG Jiamin, LIU Zhiqiang. Preparation of a Der p2 B cell epitope RNA vaccine and its specific IgE inhibition in mice with allergic rhinitis[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(5): 6-12.

参考文献

[1] Zhang Y, Lan F, Zhang L. Advances and highlights in allergic rhinitis[J]. Allergy, 2021, 76(11): 3383-3389. doi:10.1111/all.15044
[2] 程雷,钱俊俊,田慧琴. 变应性鼻炎研究的若干进展[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 1-3. doi:10.6040/j.issn.1673-3770.1.2017.021 CHENG Lei, QIAN Junjun, TIAN Huiqin. Research progresses on allergic rhinitis[J].Journal of Otolaryngology and Ophthalmology of Shandong University, 2017, 31(3): 1-3. doi:10.6040/j.issn.1673-3770.1.2017.021
[3] Bousquet J, Anto JM, Bachert C, et al. Allergic rhinitis [J]. Nat Rev Dis Primers, 2020, 6(1): 95. doi: 10.1038/s41572-020-00227-0.
[4] Durham SR, Shamji MH. Allergen immunotherapy: past, present and future[J]. Nat Rev Immunol, 2023, 23(5): 317-328.
[5] 庞冲,边赛男,张冰,等. 儿童过敏性鼻炎粉尘螨特异性舌下免疫治疗短期疗效评估[J]. 山东大学耳鼻喉眼学报,2022,36(1):70-74. doi:10.6040/j.issn.1673-3770.0.2021.117 PANG Chong, BIAN Sainan, ZHANG Bing, et al. Short-term effect of Dermatophagoides farinae specific sublingual immunotherapy for children with allergic rhinitis[ J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(1): 70-74. doi: 10.6040 / j.issn.1673-3770.0.2021.117
[6] Lee SP, Shin YS, Kang SY, et al. Recent advances in allergen-specific immunotherapy in humans: a systematic review[J]. Immune Netw, 2022, 22(1): 12. doi:10.4110/in.2022.22.e12
[7] Cantone E, Gallo S, Torretta S, et al. The role of allergen-specific immunotherapy in ENT diseases: a systematic review[J]. J Pers Med, 2022, 12(6): 946. doi:10.3390/jpm12060946
[8] Valenta R, Campana R, Niederberger V. Recombinant allergy vaccines based on allergen-derived B cell epitopes[J].Immunol Lett, 2017, 189: 19-26. doi:10.1016/j.imlet.2017.04.015
[9] Niederberger V, Neubauer A, Gevaert P, et al. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32[J]. J Allergy Clin Immunol, 2018, 142(2): 497-509.e9. doi:10.1016/j.jaci.2017.09.052
[10] Huang HJ, Sarzsinszky E, Vrtala S. House dust mite allergy: the importance of house dust mite allergens for diagnosis and immunotherapy[J]. Mol Immunol, 2023, 158: 54-67. doi:10.1016/j.molimm.2023.04.008
[11] Qin QZ, Tang J, Wang CY, et al. Construction by artificial intelligence and immunovalidation of hypoallergenic mite allergen Der f 36 vaccine[J]. Front Immunol, 2024, 15: 1325998. doi:10.3389/fimmu.2024.1325998
[12] Cevhertas L, OguLur I, Maurer DJ, et al. Advances and recent developments in asthma in 2020[J]. Allergy, 2020, 75(12): 3124-3146. doi:10.1111/all.14607
[13] Pavón-Romero GF, Parra-Vargas MI, Ramírez-Jiménez F, et al. Allergen immunotherapy: current and future trends[J]. Cells, 2022, 11(2): 212. doi:10.3390/cells11020212
[14] Nony E, BouLey J, Le Mignon M, et al. Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients[J]. Allergy, 2015, 70(7): 795-804. doi:10.1111/all.12622
[15] Focke-Tejkl M, Weber M, Niespodziana K, et al. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy[J]. J Allergy Clin Immunol, 2015, 135(5): 1207-1207.e1-11. doi:10.1016/j.jaci.2014.09.012
[16] Moten D, Kolchakova D, Todorov K, et al. Design of an epitope-based peptide vaccine against the major allergen amb a 11 using immunoinformatic approaches[J]. Protein J, 2022, 41(2): 315-326. doi:10.1007/s10930-022-10050-z
[17] Sung YK, Kim SW. Recent advances in the development of gene delivery systems[J]. Biomater Res, 2019, 23: 8. doi:10.1186/s40824-019-0156-z
[18] Roesler E, Weiss R, Weinberger EE, et al. Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens[J]. J Allergy Clin Immunol, 2009, 124(5): 1070-1077.e1-11. doi:10.1016/j.jaci.2009.06.036
[19] O guz F, Atmaca H. mRNA as a therapeutics: understanding mRNA vaccines[J]. Adv Pharm BuLl, 2022, 12(2): 274-282. doi:10.34172/apb.2022.028
[20] Hattinger E, Scheiblhofer S, Roesler E, et al. Prophylactic mRNA vaccination against allergy confers long-term memory responses and persistent protection in mice[J]. J Immunol Res, 2015, 2015: 797421. doi:10.1155/2015/797421

相关文章 15

[1]	张丽净,冯晓星,刘南仙,赵辉明,陈月华. 石墨烯养护鼻罩结合尘螨的皮下特异性免疫治疗在尘螨变应性鼻炎患者中的应用分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 26-32.
[2]	鹿伟理,姜涛,李宪华. 多重致敏儿童变应性鼻炎患者sIgE特征分析[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 260-265.
[3]	庞冲,边赛男,张冰,尹旭,陆颖霞,叶鹏飞,王湛,赵晶,高彦,关凯. 儿童过敏性鼻炎粉尘螨特异性舌下免疫治疗短期疗效评估[J]. 山东大学耳鼻喉眼学报, 2022, 36(1): 70-74.
[4]	李孟辉,郅莉莉,戚凯文,王珊珊,高倩,步美玲,姜荷云,冯绛楠,王金荣. 皮下免疫治疗对单一尘螨和合并霉菌过敏儿童哮喘的临床研究[J]. 山东大学耳鼻喉眼学报, 2022, 36(1): 75-80.
[5]	杨晴,陆美萍,程雷. 苏皖地区变应性鼻炎患者气传变应原皮肤点刺试验和血清特异性IgE检测的一致性及相关性分析[J]. 山东大学耳鼻喉眼学报, 2021, 35(1): 40-46.
[6]	林兴,沈翎,林宗通,杨中婕. 儿童鼻腔异物与过敏性鼻炎关系的初步研究[J]. 山东大学耳鼻喉眼学报, 2020, 34(4): 101-104.
[7]	张贵阳,黄河,冼志,张汉文,谢桂彩. 粉尘螨滴剂舌下含服免疫治疗对不同年龄段变应性鼻炎患者的临床效果评估[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 60-65.
[8]	钱俊俊,周文成,吴中飞,卜冬云,汪李琴,陆美萍,程雷. 苏皖地区变应性鼻炎患者吸入性变应原谱分析[J]. 山东大学耳鼻喉眼学报, 2019, 33(3): 147-151.
[9]	洪冬冬,刘元献,邹练强,翁镌凌,邓文娴. 变应性鼻炎患者粉尘螨皮肤点刺试验阳性764例结果分析[J]. 山东大学耳鼻喉眼学报, 2019, 33(1): 119-123.
[10]	邰旭辉,杨昕,朱宝玉,曹鋐,褚彦玲,单晓东,姜宇. 辽宁地区2 883例变应性鼻炎患者变应原分布特征[J]. 山东大学耳鼻喉眼学报, 2016, 30(4): 39-42.
[11]	屠燕怡,史丽,赵莉,金鹏,訾晓雪,李昂,金义炫,郅莉莉. 尘螨疫苗皮下注射治疗变应性鼻炎的疗效和安全性评估[J]. 山东大学耳鼻喉眼学报, 2016, 30(4): 50-55.
[12]	顾晓,陈彦林. 舌下免疫治疗变应性鼻炎的疗效分析[J]. 山东大学耳鼻喉眼学报, 2016, 30(1): 17-20.
[13]	谢晓红, 胡志邦, 宋盼盼, 戴艳红, 陈峰, 俞晨杰, 高下. 舌下含服粉尘螨滴剂联合鼻用激素治疗变应性鼻炎疗效观察[J]. 山东大学耳鼻喉眼学报, 2014, 28(5): 34-37.
[14]	岳耀光，黄合银，黄丽芳，梁仕才，蒙周君，邓斯敏，张永强，吕显林，李亿华，沈诚. 舌下含服粉尘螨滴剂治疗儿童变应性鼻炎合并腺样体肥大的疗效观察[J]. 山东大学耳鼻喉眼学报, 2014, 28(3): 16-19.
[15]	杨阳1，2，刘吉祥2，宋富存2，程莉雅1. 尘螨变应原皮肤点刺试验结果与其血清sIgE及年龄的相关性[J]. 山东大学耳鼻喉眼学报, 2014, 28(2): 65-67.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed